China Meheco To Acquire Holley Pharmaceuticals’ Subsidiary
This article was originally published in PharmAsia News
Executive Summary
China Meheco has signed an in-principle agreement with the shareholders of Beijing Holley Jiuzhou Pharmaceuticals to acquire 100 percent of the firm with cash. Holley Jiuzhou is 88.24 percent owned by Holley Pharmaceuticals (Chongqing) and 11.76 percent held by HolleyPharm's investment arm. The purchase, if approved by the three parties' respective boards and majority shareholders, will facilitate China Meheco's expansion of its drug distribution network and business. The company expects the acquisition to help it achieve sales revenue and profit of 1 billion yuan and 5 million yuan respectively. (Click here for more - Chinese Language)
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.